Market Overview

UPDATE: Swedbank Downgrades AstraZeneca to Sell; Margins Under Pressure

Related AZN
Deutsche Bank Says Pfizer Has A Strong Financial Position And Attractive Pipeline
The 4 Companies Teaming Up For A New Tool To Fight Cancer
Treasury Develolping Options to Curb Inversions (Fox Business)

Swedbank downgraded AstraZeneca (NYSE: AZN) from Reduce to Sell.

Swedbank noted, "Later in March, AstraZeneca will stage its first CMD with a new strategy and a new leadership. It is already clear that this will involve committed investments to transform the pipeline's size and potential. Together with the top-line pressure, this should squeeze the short-term earnings. Upside should be revealed gradually after 2015."

AstraZeneca closed at $45.80 on Thursday.

Posted-In: SwedbankAnalyst Color Downgrades Analyst Ratings

 

Related Articles (AZN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters